Erasca, Inc. (ERAS) NASDAQ
17.01
-0.35(-2.02%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
17.01
-0.35(-2.02%)
Currency In USD
| Previous Close | 17.36 |
| Open | 17.44 |
| Day High | 17.51 |
| Day Low | 16.59 |
| 52-Week High | 18.2 |
| 52-Week Low | 1.06 |
| Volume | 2.74M |
| Average Volume | 5.57M |
| Market Cap | 5.29B |
| PE | -38.66 |
| EPS | -0.44 |
| Moving Average 50 Days | 14.02 |
| Moving Average 200 Days | 5.64 |
| Change | -0.35 |
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau
GlobeNewswire Inc.
Mar 10, 2026 12:00 PM GMT
Worldwide rights position Erasca to advance ERAS-0015 through a unified global development strategy ERAS-0015’s promising early clinical data underscore its potential to be a best-in-class RAS-targeting agent Initial Phase 1 monotherapy data for ERAS
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat
GlobeNewswire Inc.
Mar 05, 2026 12:01 PM GMT
ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Na
Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca’s diversified IP portfolio for RAS-driven cancers Initial Phase 1 monotherapy data expected for ERAS-0015 in 1H and